Brecanavir
From Wikipedia, the free encyclopedia
Brecanavir
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | ? |
Chemical data | |
Formula | C33H41N3O10S2 |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]
On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]
[edit] References
- ^ Hazen R, Harvey R, Ferris R, et al (September 2007). "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV". Antimicrob. Agents Chemother. 51 (9): 3147–54. doi: . PMID 17620375.
- ^ GlaxoSmithKline (2006-12-18). "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)". Press release. Retrieved on 2008-06-11.
|